Clinical trials: Neoadjuvant Radiotherapy
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Plus Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma This is a prospective, randomized, two-arm, parallel-group, multicenter…
- Trial name
- NCT07678580
- Testing
- Albumin-bound paclitaxel, Low-dose Short-course Radiotherapy, High-dose Short-course Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamous Cell Carcinoma
Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)
Esophageal squamous cell carcinoma (ESCC), one of the most common subtypes of esophageal cancer, has a poor prognosis and low 5-year overall survival.
- Trial name
- TINES (NCT05603065)
- Testing
- Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Lung Cancer, Small Cell, Limited-stage Small Cell Lung Cancer (LS-SCLC)
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Radiotherapy can activate local and systemic immune responses through a variety of mechanisms, which can enhance anti-tumor immune effects.
- Trial name
- NCT06914050
- Testing
- Adebrelimab, EC/EP, SBRT
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Neoplasms
Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer
The current standard treatment for patients with primarily resectable pancreatic tumors consists of surgery followed by adjuvant chemotherapy.
- Trial name
- NEOPANC (NCT01372735)
- Testing
- neoadjuvant short course IMRT, IORT
- Where
- 3 sites in Germany
- Volunteers
- 46 people
- Sponsor
- University Hospital Heidelberg
Head and Neck Cancer
Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002747
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- European Institute of Oncology
Rectal Cancer
Minimally Invasive Sphincter Sparing Total Mesorectal Excision for Ultra-low Rectal Cancer After Initial Chemo-radiotherapy (MISS-TRICR).
A prospective study is planned for management of low rectal cancer with the aim of sphincter preservation and improving the oncological outcome of the patients, through comparing of both approaches minimally invasive techniques…
- Trial name
- MISS-TRICR (NCT02488707)
- Testing
- laparoscopic intersphincteric resection (LISR group), Transanal minimally invasive Total mesorectal excision (TAMIS group)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Mansoura University
Rectal Adenocarcinoma
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
A Prospective Single-Arm Study of Short-Course Radiotherapy Followed by PD-1 Monoclonal Antibody, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil for Total Neoadjuvant Therapy in MSS Locally Advanced Low Rectal Cancer.
- Trial name
- SCRIPBOT (NCT06872606)
- Testing
- Pucotenlimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Locally Advanced Rectal Cancer (LARC), 5-12cm to Anal Verge
Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study aims to observe and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab（QL-1706） combined with chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy in patients with locally advanced rectal…
- Trial name
- IT-CABLE (NCT07769853)
- Testing
- Iparomlimab and Tuvonralimab（QL-1706）combined with Chemotherapy and Bevacizumab
- Volunteers
- 56 people
- Sponsor
- Zhejiang University
Breast Cancer
Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00647218
- Testing
- Post-operative adjuvant therapy, neoadjuvant therapy, therapeutic surgical procedure
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma, Squamous Cell of Head and Neck
Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy
Verify the effect and the incidence of oral mucositis of concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy.
- Trial name
- NCT02753140
- Testing
- Cetuximab, radiation, Docetaxel
- Volunteers
- 60 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Rectal Cancer
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
The standard treatment for rectal cancer is to receive the chemotherapeutic drug 5-fluorouracil (5-FU) with radiation therapy before having surgery to remove the rectal cancer. This is known as neoadjuvant chemoradiotherapy.
- Trial name
- NCT00611858
- Testing
- Cetuximab, 5-Fluorouracil, Radiation
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced Rectal Cancer (LARC), Immunotherapy
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
The study is a multicenter, randomized controlled, phase III clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy
- Trial name
- NCT07020247
- Testing
- Anti-PD-1 antibody drug named Serplulimab, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 184 people
- Sponsor
- West China Hospital
Head and Neck Cancer
Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery
Primary diagnose HNSCC carcinoma patients eligible for curative surgery will be proposed the addition of 2 or 3 neoadjuvant cetuximab infusions.
- Trial name
- CHIRON (NCT00714649)
- Testing
- cetuximab
- Where
- Belgium
- Volunteers
- 34 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Rectal Neoplasms
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Given the growing focus on preserving organ function and the utilization of neoadjuvant therapy, it is important to investigate and enhance the application of comprehensive neoadjuvant therapy in low rectal cancer.
- Trial name
- NCT06417476
- Testing
- Short-course radiotherapy, Irinotecan, Oxaliplatin
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Pei-Rong Ding
Breast Cancer
Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
The study is being conducted to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) combined neoadjuvant treatment for patients with triple-negative and hormone receptor-positive, HER2-negative breast…
- Trial name
- NCT05132790
- Testing
- SHR-1316 at a dose 20mg/kg q3w, SHR6390 at a dose of 150mg orally, daily, SBRT
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shengjing Hospital
Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Since patients with (borderline) resectable pancreatic cancer have a limited life expectancy, it is important to improve treatment strategies.
- Conditions
- Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-5 (NCT06384560)
- Testing
- Pembrolizumab, Folfirinox, SABR
- Where
- 4 sites in Netherlands
- Volunteers
- 66 people
- Sponsor
- Amsterdam UMC, location VUmc
Neoadjuvant Treatment, Rectal Cancer
Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type locally advanced rectal cancer
- Conditions
- Neoadjuvant Treatment, Rectal Cancer, Cetuximab, Radiotherapy
- Trial name
- NCT04923620
- Testing
- cetuximab+mFOLFOX6, short-course radiotherapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Renal Cell Carcinoma, Clear Cell, Somatic
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
This is a prospective, open label, phase II, randomised, non-comparative clinical trial, evaluating changes in tumour-responsive T-cells following neoadjuvant stereotactic ablative body radiotherapy (SABR) with or without…
- Trial name
- NAPSTER (NCT05024318)
- Testing
- Pembrolizumab, Stereotactic Ablative Radiotherapy, Nephrectomy
- Where
- 2 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin and flutamide may fight cancer by reducing the production of androgens.
- Trial name
- NCT00003734
- Testing
- flutamide, triptorelin, radiation therapy
- Where
- 12 sites in Ireland, United Kingdom
- Volunteers
- 276 people
- Sponsor
- St. Luke's Hospital, Ireland
Brain Metastases
Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis
This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the…
- Trial name
- NeoSTROBE (NCT06933199)
- Testing
- Neoadjuvant Stereotactic Radiotherapy (NaSRT), Postoperative Stereotactic Radiotherapy (SRT)
- Where
- 4 sites in Czechia
- Volunteers
- 260 people
- Sponsor
- University Hospital Ostrava